Anna Howard

Anna Schwamlein Howard is the Medicare Reimbursement & Health Policy Director on the firm’s Lobbying & Advocacy team.

A nationally recognized authority on health care reform issues, Anna has considerable experience in government relations and regulatory affairs. Specifically, she has extensive knowledge with the Medicare Modernization Act, medical privacy and prescription drug issues, Medicare physician payment legislation, the Affordable Care Act, and other federal health issues impacting the lives of older Americans.

Prior to joining Drinker Biddle, Anna was a Senior Legislative Representative for AARP’s Federal Affairs Health and Long-Term Care Team. In this capacity Anna represented the interests of the 50+ population before the legislative and executive branches of government for a wide variety of health care matters, with a particular emphasis on Medicare and prescription drug issues. Anna has authored numerous congressional testimonies and other health policy materials related to health care issues that impact the 50+ population.

Anna earned her B.A. in Political Science from The American University and graduated, cum laude, from The American University’s Washington College of Law.



From the Blog

Overlapping Post-Marketing Challenges for Biopharmaceuticals: Pharamacovigilance, Products Liability, and Biosmiliars

Krista Cosner published, “Overlapping Post-Marketing Challenges for Biopharmaceuticals: Pharmacovigilance, Products Liability, and Biosimilars,” in the following publications: Bloomberg Services (May 16), BioTech Watch (May...

Privately Held Medical Device and Drug Companies Face Unique Sunshine Act Challenges

As widely reported, the Centers for Medicare and Medicaid Services (“CMS”) recently issued regulations implementing the Sunshine Act provisions of the Affordable Care Act. ...

What Goes Up…Must Come Down: Viagra patent invalidated by Canadian Supreme Court

Pfizer and Teva have been fighting a legal battle over Pfizer’s patent for Viagra in Canada.  The first shot was fired when Novopharm Limited,...